Following the advancement in molecular biology and recombinant technology, the protein and polypeptide therapeutics have become an important class of clinical drugs due to their unique superiority. However, the problems of stability and short half-life of proteins and peptides also vastly limit their further use in clinic. The focal points of this paper are to introduce the specific ways and the matters needing attention to increase the biological half-life of the therapeutic protein and polypeptide drugs.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!